Hepatitis B serosurvey to validate the achievement of regional hepatitis B control targets in Belarus

IF 4.5 3区医学 Q2 IMMUNOLOGY Vaccine Pub Date : 2025-05-10 Epub Date: 2025-03-27 DOI:10.1016/j.vaccine.2025.127058

Veronika Vysotskaya , Martyna Gassowski , Amelia Kasper , Elena Gasich , Natalia Kolomiets , Alla Dashkevich , Kathleen Wannemuehler , Oleg Dubovik , Liudmila Mosina

{"title":"Hepatitis B serosurvey to validate the achievement of regional hepatitis B control targets in Belarus","authors":"Veronika Vysotskaya , Martyna Gassowski , Amelia Kasper , Elena Gasich , Natalia Kolomiets , Alla Dashkevich , Kathleen Wannemuehler , Oleg Dubovik , Liudmila Mosina","doi":"10.1016/j.vaccine.2025.127058","DOIUrl":null,"url":null,"abstract":"<div><div>Belarus conducted a representative, national hepatitis B serosurvey to evaluate the impact of hepatitis B vaccination programme.</div><div>We used a multi-stage cluster design to select 3783 children born between 2009 and 2015. We collected demographic and immunization data, as well as venous blood samples, which were analysed for HBsAg by ELISA.</div><div>Out of 2870 participants with valid test results, one tested positive for HBsAg, resulting in a weighted seroprevalence of 0.02% (one-sided 95% upper bound = 0.09%). Of the 3731/3783 (99%) participants with immunization records, 86.8% (95% CI: 84.8; 88.6) had received a timely birth dose of hepatitis B vaccine and 85.6% (95% CI: 83.5; 87.4) had received a birth dose and at least two subsequent doses of the vaccine.</div><div>This study findings demonstrated the achievement of the regional hepatitis B control targets and significant progress toward the elimination of hepatitis B as a public health threat in Belarus.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"55 ","pages":"Article 127058"},"PeriodicalIF":4.5000,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X2500355X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/27 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Belarus conducted a representative, national hepatitis B serosurvey to evaluate the impact of hepatitis B vaccination programme.

We used a multi-stage cluster design to select 3783 children born between 2009 and 2015. We collected demographic and immunization data, as well as venous blood samples, which were analysed for HBsAg by ELISA.

Out of 2870 participants with valid test results, one tested positive for HBsAg, resulting in a weighted seroprevalence of 0.02% (one-sided 95% upper bound = 0.09%). Of the 3731/3783 (99%) participants with immunization records, 86.8% (95% CI: 84.8; 88.6) had received a timely birth dose of hepatitis B vaccine and 85.6% (95% CI: 83.5; 87.4) had received a birth dose and at least two subsequent doses of the vaccine.

This study findings demonstrated the achievement of the regional hepatitis B control targets and significant progress toward the elimination of hepatitis B as a public health threat in Belarus.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

进行乙型肝炎血清调查，以验证白俄罗斯实现了区域乙型肝炎控制目标

白俄罗斯进行了一项有代表性的全国乙型肝炎血清调查，以评估乙型肝炎疫苗接种方案的影响。我们采用多阶段聚类设计，选取了2009年至2015年间出生的3783名儿童。我们收集了人口统计和免疫数据，以及静脉血样本，用ELISA分析HBsAg。在具有有效检测结果的2870名参与者中，1名HBsAg检测呈阳性，导致加权血清阳性率为0.02%（单侧95%上限= 0.09%）。在3731/3783（99%）有免疫记录的参与者中，86.8% (95% CI: 84.8；88.6)和85.6% (95% CI: 83.5；（87.4）已接种了一剂出生疫苗和至少两剂后续疫苗。这项研究结果表明，白俄罗斯实现了区域乙型肝炎控制目标，并在消除作为公共卫生威胁的乙型肝炎方面取得了重大进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Vaccine 医学-免疫学

CiteScore

8.70

自引率

5.50%

发文量

992

审稿时长

131 days

期刊介绍： Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.